Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa.

@article{Ferreri2005RituximabIP,
  title={Rituximab in patients with mucosal-associated lymphoid tissue-type lymphoma of the ocular adnexa.},
  author={Andr{\'e}s J M Ferreri and Maurilio Ponzoni and Giovanni Martinelli and Giuliana Muti and Massimo Guidoboni and Riccardo Dolcetti and Claudio Doglioni},
  journal={Haematologica},
  year={2005},
  volume={90 11},
  pages={1578-9}
}
Eight patients with ocular adnexal mucosal-associated lymphpid tissue (MALT) lymphoma were treated with rituximab, at diagnosis (n=5) or relapse (n=3). All untreated patients achieved lymphoma regression, while relapsing patients had no benefit. Four responding patients experienced early relapse. The median time to progression was 5 months. The efficacy of rituximab in ocular adnexal lymphoma is lower than that reported for gastric MALT lymphomas. 

Citations

Publications citing this paper.
Showing 1-10 of 37 extracted citations

Treatment options for ocular adnexal lymphoma (OAL)

Clinical ophthalmology • 2009
View 3 Excerpts
Highly Influenced

Manual of Oculoplastic Surgery

Springer International Publishing • 2018

Similar Papers

Loading similar papers…